Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders

January 30, 2024 12:00 AM AEDT | By Cision

Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders — Image source: Kalkine Media

Recent News

Construction durable: Les tendances canadiennes et mondiales décryptée...

CORRECTING and REPLACING RSA Announces New Innovations to Stop Help De...

US Treasury sells $42B 10-year notes at lower-than-expected yield

247connect Makes Remote Desktop Access Simple and Affordable!

SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the charge in small activating RNA (saRNA) therapeutics, announces a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University. This strategic alliance unites their respective strengths to advance the development of saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.

Professor Bobby Koeleman, Group Leader at the Department of Genetics within the Center for Molecular Medicine at Utrecht University, will lead the collaboration with Ractigen Therapeutics. By synergistically leveraging Ractigen's cutting-edge saRNA discovery platform, medicinal chemistry expertise, and innovative oligonucleotide delivery systems, the partnership aims to translate promising preclinical research into clinically efficacious therapeutics. Professor Koeleman's research team, lauded for their work in elucidating the genetic underpinnings of severe childhood epilepsies, will contribute novel gene targets brimming with therapeutic potential.

This partnership represents a practical approach to integrating academic research with industry capabilities to develop potential treatments for neurodevelopmental disorders. Through this collaboration, Ractigen's technology and Utrecht University's research are expected to contribute significantly to the field of saRNA therapeutics and therapeutic development for neurodevelopmental disorders.

Dr. Long-Cheng Li, CEO of Ractigen Therapeutics, commented on the collaboration: "Our partnership with Utrecht University represents a significant step forward in our mission to develop innovative therapies for challenging genetic disorders. By combining our RNAa technology and advanced delivery systems with Utrecht's impactful research, we believe we can make a real difference in the field of neurodevelopmental disorders."

About University Medical Center Utrecht

The University Medical Center Utrecht is one on the biggest public healthcare institutions in the Netherlands. It is affiliated with the Utrecht University. Professor Koeleman is an expert in genetics, dedicated to find genetic causes of both common and rare genetic disease, and subsequently aims to translate the genetic finding to clinical relevance. His group focuses in developing small activating RNAs (saRNAs) for genes associated with severe childhood epilepsies.

About Ractigen Therapeutics

Ractigen Therapeutics is at the forefront of developing saRNA drugs, utilizing the RNAa mechanism to up-regulate endogenous gene expression. This cutting-edge approach harnesses the power of saRNA to specifically target and enhance the transcription of target genes, thereby restoring their normal protein function. By overcoming gene silencing or insufficient protein production through targeted upregulation, Ractigen tackles previously intractable conditions, offering renewed hope to patients and families impacted by a range of complex genetic disorders.

Contact Information:
Ractigen Therapeutics
www.ractigen.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.